The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACXP | -79.22% | N/A | N/A | -98% |
| S&P | +13.09% | +85.73% | +13.17% | +60% |
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
No news articles found for Acurx Pharmaceuticals.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $6.80M | -78.7% |
| Market Cap / Employee | $1.70M | 0.0% |
| Employees | 4 | 0.0% |
| Net Income | -$1.99M | 29.4% |
| EBITDA | -$2.03M | 28.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.91M | 2.5% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -151.72% | 98.4% |
| Return On Invested Capital | -608.07% | -313.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.88M | 14.1% |
| Operating Free Cash Flow | -$1.88M | 14.1% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 22.54 | 3.78 | 4.21 | 1.77 | -85.21% |
| Price to Tangible Book Value | 102.49 | 215.96 | 98.99 | 1.77 | -99.00% |
| Enterprise Value to EBITDA | -3.65 | -1.48 | -2.69 | -0.53 | -94.14% |
| Return on Equity | -534.0% | -285.8% | -285.9% | -291.1% | -41.57% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
